Peripheral
SFA

When endovascular is not the only answer

The debate between open surgery and endovascular therapy is far from over. This PVI 2025 session explores complex revascularisation scenarios where the choice of strategy requires careful consideration of anatomy, previous interventions and patient profile. 

Starting with common femoral artery disease, experts discuss surgical options after failed stenting and demonstrate why open repair remains feasible in most cases — challenging the idea that stenting should always be avoided in this challenging segment.

The discussion then moves to failed bypasses, highlighting situations where endovascular treatment may offer a valuable alternative, even when a suitable vein is available. 

Finally, the panel revisits the role of bypass in chronic limb-threatening ischaemia after BASIL-2, emphasising that while many lesions can be treated endovascularly, “endo first” is not always the optimal approach. 

Ultimately, the optimal revascularisation strategy is not defined by an “endo first” or “open first” philosophy, but by selecting the right approach for the right patient.

 

Hospital: Paris Saint-Joseph, France

Professor of Vascular Surgery 
President of the association of the french university hospitals for clinical research 

Conflicts of interest:

Research funding from Predisurge, Biotronik, WL Gore, GE Healthcare 
Honoraria from Abbott, BD, Bentely, Biotronik, Boston Scientific, Cook, Eclevar Medtech, GE Healthcare, Ivascular, Medtronic, Penumbra, Sensome, Shockwave medical, WL Gore (consulting, medical advisory board, educational course, speaking)

Berlin, Germany
Genk, Belgium
New York, United States
San Francisco, United States

You must be logged in or create an account to see all the content